Sugi Predict

Sugi Predict / Compounds / SCHEMBL754129

SCHEMBL754129

SCHEMBL754129

COC(=O)N[C@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 5/20 0.59
▸ FPR2 P25090 2/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.58
▸ ACE P12821 5/20 0.58
▸ ALDH1A1 P00352 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ NAALAD2 Q9Y3Q0 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ CPA1 P15085 4/20 0.55
▸ ACE2 Q9BYF1 4/20 0.55
▸ ATM Q13315 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL27550557 1.00 MME (0.59) MMEFPR2L3MBTL1NPSR1ACE
SCHEMBL627437 1.00 MME (0.59) MMEFPR2L3MBTL1NPSR1ACE
Benzene SCHEMBL27550555 1.00 MME (0.59) MMEFPR2L3MBTL1NPSR1ACE
Benzene SCHEMBL27569477 1.00 MME (0.59) MMEFPR2L3MBTL1NPSR1ACE
SCHEMBL205548 1.00 MME (0.59) MMEFPR2L3MBTL1NPSR1ACE
SCHEMBL2720887 0.95 MME (0.61) MMEFPR2L3MBTL1ACECPA1
SCHEMBL24534147 0.94 MME (0.61) MMEFPR2L3MBTL1ACEALDH1A1
SCHEMBL24534148 0.94 MME (0.61) MMEFPR2L3MBTL1ACEALDH1A1
SCHEMBL19888359 0.92 MME (0.65) MMEACECPA1ACE2
SCHEMBL2720880 0.92 MME (0.65) MMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210130341-A1 HPTP-BETA INHIBITORS EyePoint Pharmaceuticals, Inc. 2021-05-06 — — US disclosed
US-10858354-B2 HPTP-Beta inhibitors Aerpio Pharmaceuticals, Inc. (US) 2020-12-08 — — US disclosed
US-9994560-B2 HPTP-β inhibitors AERPIO THERAPEUTICS, INC. (US) 2018-06-12 — — US disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 — — US disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 — — EP disclosed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 — — US disclosed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 — — US disclosed
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-11-09 — — US disclosed
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-11-09 — — US disclosed
EP-2601188-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-18 — — EP disclosed
US-20050107378-A1 Heterocyclic amines having central nervous system activity ROMERO ARTHUR G (US) 2005-05-19 — — US disclosed
US-RE38452-E1 SUITABLE FOR TREATING ANXIOLYTIC DISORDER, SCHIZOPHRENIA, PARKINSON'S DISEASE, ANXIETY PHARMACIA & UPJOHN COMPANY 2004-03-02 — — US disclosed
US-20020187981-A1 Heterocyclic amines having central nervous system activity ROMERO ARTHUR GLENN (US) 2002-12-12 — — US disclosed
US-20010009916-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY ROMERO ARTHUR G (US) 2001-07-26 — — US disclosed
CN-1043574-C Heterocyclic amines having central nervous system activity UPJOHN CO (US) 1999-06-09 — — CN disclosed
EP-0724584-B1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY UPJOHN CO (US) 1997-11-05 — — EP disclosed
US-5652245-A Heterocyclic amines having central nervous system activity PHARMACIA & UPJOHN COMPANY (US) 1997-07-29 — — US disclosed
EP-0724584-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY PHARMACIA & UPJOHN COMPANY (US) 1996-08-07 — — EP disclosed
CN-1128030-A Heterocyclic amines having central nervous system activity UPJOHN CO (US) 1996-07-31 — — CN disclosed
WO-1995004056-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY THE UPJOHN COMPANY (US) 1995-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR HAVCR2, LIPC, PYGL MME 1155/4885FPR2 3926/4885L3MBTL1 3648/4885
US-20010009916-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY CNR1, CNR2, OPRD1 MME 2165/4885FPR2 551/4885L3MBTL1 3907/4885
US-20210130341-A1 HPTP-BETA INHIBITORS TEK, TIE1, PITPNB MME 1233/4885FPR2 2058/4885L3MBTL1 4061/4885
US-10858354-B2 HPTP-Beta inhibitors TEK, TIE1, PITPNB MME 1233/4885FPR2 2058/4885L3MBTL1 4061/4885
US-20020187981-A1 Heterocyclic amines having central nervous system activity CNR1, CNR2, OPRD1 MME 2119/4885FPR2 553/4885L3MBTL1 3875/4885
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS MME 1382/4885FPR2 3812/4885L3MBTL1 3763/4885
US-20050107378-A1 Heterocyclic amines having central nervous system activity CNR1, CNR2, NPY2R MME 3444/4885FPR2 394/4885L3MBTL1 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.